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Abstract
Aims/hypothesis Non-invasive diagnostic tools specific for
pancreatic beta cells will have a profound impact on our
understanding of the pathophysiology of metabolic diseases
such as diabetes. The objective of this study was to use
molecular imaging probes specifically targeting beta cells
on human samples and animal models using state-of-the-art
imaging modalities (fluorescence and PET) with preclinical
and clinical perspective.
Methods We generated a monoclonal antibody, 8/9-mAb,
targeting transmembrane protein 27 (TMEM27; a surface
N-glycoprotein that is highly expressed on beta cells), com-
pared its expression in human and mouse pancreas, and
demonstrated beta cell-specific binding in both. In vivo
imaging was performed in mice with subcutaneous insuli-
nomas overexpressing the human TMEM27 gene, or
transgenic mice with beta cell-specific hTMEM27 expres-
sion under the control of rat insulin promoter (RIP-
hTMEM27-tg), using fluorescence and radioactively
labelled antibody, followed by tissue ex vivo analysis and
fluorescence microscopy.
Results Fluorescently labelled 8/9-mAb showed beta cell-
specific staining on human and mouse pancreatic sections.
Real-time PCR on islet cDNA indicated about tenfold
higher expression of hTMEM27 in RIP-hTMEM27-tg mice
than in humans. In vivo fluorescence and PET imaging in
nude mice with insulinoma xenografts expressing
hTMEM27 showed high 8/9-mAb uptake in tumours after
72 h. Antibody homing was also observed in beta cells of
RIP-hTMEM27-tg mice by in vivo fluorescence imaging.
Ex vivo analysis of intact pancreas and fluorescence micro-
scopy in beta cells confirmed these findings.
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Conclusions/interpretation hTMEM27 constitutes an
attractive target for in vivo visualisation of pancreatic
beta cells. Studies in mouse insulinoma models and
mice expressing hTMEM27 demonstrate the feasibility
of beta cell-targeted in vivo imaging, which is attractive
for preclinical investigations and holds potential in clinical
diagnostics.
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Abbreviations
%ID Percentage of injected dose
AF Alexa Fluor
BACE Beta-secretase
FMT Fluorescence molecular tomography
HA Haemagglutinin
mAb Monoclonal antibody
PET Positron emission tomography
RIP Rat insulin promoter
ROI Region of interest
TMEM27 Transmembrane protein 27
Introduction
Diabetes is a progressive disease ultimately leading to loss
of pancreatic beta cells, which produce and secrete insulin to
maintain glucose homeostasis. With a chronically increasing
demand for insulin in response to an increased metabolic
load and peripheral insulin resistance, beta cells adapt by
altering both functionality and mass [1–5]. Gradual loss of
beta cells and their function causes hyperglycaemia and
eventually type 2 diabetes [2, 6–8]. Today, an estimated
300 million people have impaired glucose tolerance, while
another 600 million are suffering from fully established
diabetes [9]. Non-invasive monitoring of beta cell changes
in vivo could serve as an early indicator of diabetes and
accelerate the clinical development of novel, possibly pre-
ventive, therapies. Molecular imaging could provide spe-
cific tools for detecting beta cell mass and even functionality
in vivo [10–12]. Beta cells constitute only 1% of the total
pancreatic mass, and their scattered organisation in islets of
Langerhans within the largely exocrine pancreas makes
development and use of cell-specific imaging tools chal-
lenging. Moreover, the anatomical location of the pancreas
next to large organs involved in drug/label metabolism and
excretion makes it difficult to access by imaging-based
approaches.
A variety of strategies for imaging beta cells based on
MRI, positron emission tomography (PET) and optical
imaging are being explored [13]. Probes such as dihydrote-
trabenazine, sulfonylurea secretagogues and somatostatin
receptor analogues have been evaluated as potential beta
cell-detection agents. The ligand dihydrotetrabenazine, tar-
geting the vesicular monoamine transporter 2 expressed on
the pancreatic beta cells, is the most promising candidate for
imaging pancreatic beta cells in vivo [12, 14]. Alternative
methods allow exploitation of physiological properties of
pancreatic islet structures with imaging. One example is
MRI-based non-targeted superparamagnetic nanobeads,
which have been used to visualise peri-islet vascular leakage
due to insulitis [15]. Because of its sensitivity and clinical
translatability, PET is the modality of choice for non-
invasive imaging of molecular and cellular targets [16],
although high-energy ionising radiation and the half-life of
the radioisotopes may limit achievement of a high signal-to-
background ratio [17]. For experimental studies, fluores-
cence imaging is an attractive alternative to PET, and fluo-
rescent probes can be readily used for histological validation
of in vivo imaging results. However, the major limitation of
optical imaging is photon scattering by the biological tissue,
which renders recovery of geometrical information difficult
and limits penetration depth [18]. Therefore, for imaging
beta cells in vivo, we examined both optical and PET imag-
ing as tools for research and clinical translation, respec-
tively, using an antibody-based approach.
Given the diffuse distribution of beta cells in the pan-
creas, it is important to identify a beta cell-specific molec-
ular target with high affinity. Studies on gene expression in
beta cells in the pancreas have shown that the transmem-
brane protein, TMEM27, is selectively expressed on the
beta cell surface [19] and in kidney collecting ducts [20].
Here we report on the characterisation of a monoclonal
antibody, 8/9-mAb, specific to human TMEM27 (hTMEM27),
which, upon suitable labelling, could be used for specific
imaging of beta cells in vivo by fluorescence or PET imaging.
The specificity of fluorescently labelled 8/9-mAb was eval-
uated in human tissue sample microarrays and pancreatic
sections from transgenic mice expressing hTMEM27 under
the control of rat insulin promoter (RIP-hTMEM27-tg).
The biodistribution of the antibody and its binding to
hTMEM27 in vivo were assessed in a nude mouse
subcutaneous insulinoma model expressing high levels
of hTMEM27. Finally, target-specific in vivo imaging
was used to assess beta cells in RIP-hTMEM27-tg mice.
Methods
Experimental animals All procedures were in accordance
with the Cantonal Veterinary Office in Zurich. C57BL6
mice and BALB/c nude mice were from Charles River
Laboratories (Sulzfeld, Germany). RIP-hTMEM27-tg mice
were generated in-house (M. Stoffel). All animals used in
this study were matched for sex and age.
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Vectors and stable cell lines hTMEM27 is cloned in the
pTRE vector (Clontech/Takara Bio, Saint-Germain-en-
Laye, France). Clonal selection was used to generate cell
lines stably transfected with a pTRE-TMEM27 construct as
described by Wang and Iynedjian [21].
Cell culture and transfections Rat insulinoma INS-1E
cells were obtained from C. Wolheim’s laboratory, Gen-
eva University, Switzerland and grown according to
standard laboratory protocol [22]. For stable cell lines
carrying the pTRE-hTMEM27 construct (INS-1E-
hTMEM27), the culture medium also contained the anti-
biotic, G418 (400 μg/ml; Sigma-Aldrich), to maintain
the construct, and doxycycline (20 μg/ml), to induce
human TMEM27 gene expression [21].
Tumour generation The animals were injected subcutane-
ously in the left thigh with either 3×106 cultured INS-1E or
INS-1E-hTMEM27 cells in 100 μl saline (154 mmol/l
NaCl). The tumour-bearing mice were administered
200 ng/ml doxycycline hydrochloride in drinking water to
induce hTMEM27 gene expression [21], with sucrose (1%)
added to ameliorate the bitter taste.
Antibody generation and labelling mAb against hTMEM27
(8/9-mAb) was generated by whole-cell immunisation with
repeated injections of living INS-1E-hTMEM27 cells as
described by Köhler and Milstein [23], at F. Hoffmann-La
Roche Pharmaceuticals, Basel AG. The 8/9-mAb was con-
jugated to Alexa Fluor (AF) 488 or AF 680 (A200000;
Molecular Probes, Eugene, OR, USA). The quality of the
conjugate was analysed by immunofluorescence in serial
dilutions of the antibodies on INS-1E-hTMEM27 cells.
89Zr–8/9-mAb conjugates were prepared by conjugating
8/9-mAb with p-isothiocyanatobenzyl-desferrioxamine (SCN-
Bz-DF; Macrocyclics, Dallas, TX, USA) [24], Df-8/9-mAb.
89Zr was produced by irradiating natural yttrium (89Y) with
protons at the 72 MeV accelerator of the Paul Scherrer
Institute (Villigen, Switzerland) as described by Hohn et al
[25]. Df-8/9-mAb (1.5 mg/ml) was added to 89Zr (100–
200 MBq) in 1 mol/l oxalic acid neutralised to pH 7.8 and
allowed to react for 30 min at 37°C. The conjugate was then
purified by size-exclusion chromatography on a Sepharose 12
column (GE Healthcare Life Sciences, UK) with PBS as run-
ning buffer.
Human versus mouse islet mRNA quantification Human
islets were obtained from six independent cadaver donors
through the European Consortium of Islet Transplantation
(ECIT) supported by the Juvenile Diabetes Research Foun-
dation (JDRF) in the course of 2008–2010. The islets used
were frozen 1 week after isolation, after 2 h incubation at
37°C in CMRL (Connaught Medical Research Laboratories)
medium (GibcoBRL, CA, USA) upon arrival at our loca-
tion. Murine islets were isolated from C57Bl6 (five) or RIP-
TMEM27 (four) mice using a standard mouse islet-isolation
protocol, and were frozen 2 h after isolation. RNA was
isolated using Trizol (Invitrogen, Life Technologies, Zug,
Switzerland), genomic DNA was digested using the DNA-
free kit (Ambion, Life Technologies, Zug, Switzerland), and
400 ng RNA per sample was reverse transcribed using the
Superscript III kit (Invitrogen, Life Technologies, Zug,
Switzerland). The primer pairs used to quantify total PDX1
and hTMEM27 cDNA were as given in the ESM. Tab All
primer pairs were used at an annealing temperature of 60°C,
when all pairs amplified single bands from the islet cDNA
and showed no PCR product in the non-Superscript-
treated control samples. Quantitative PCR was per-
formed on a Stratagene RT-PCR machine.
Near-infrared frequency imaging Mice bearing subcutane-
ous tumours were anaesthetised with 2% isoflurane (Attane;
Minrad, Buffalo, NY, USA) in oxygen/air mixture (1:4, vol./
vol.). Animals were imaged on a prewarmed (37°C) plat-
form in the small-animal imaging system, with maintained
anaesthesia. Control (C57BL6) and RIP-hTMEM27-tg mice
(n03–4) or subcutaneous tumour-bearing nude mice (both
INS-1E-hTMEM27 and INS-1E tumours) were adminis-
tered 2 mg/kg AF 680–8/9-mAb or AF 680–anti-haemag-
glutinin (HA)-mAb i.v. via the tail vein and imaged in vivo
longitudinally for the next 6 days.
Fluorescence molecular tomography In vivo imaging was
performed on a home-made fluorescence molecular tomog-
raphy (FMT) system [26]. For each animal (n03), a region
of interest (ROI) containing the tumour was excited by
scanning at 671 nm using a continuous-wave laser source
across the ROI. The images were recorded with an Andor
iKon CCD camera (LOT-Oriel, Moulin-du-Choc, Switzer-
land). The FMT data were reconstructed using the normal-
ised Born approximation using the slab approximation [27].
For quantification, the mean reconstructed fluorescence
intensity was computed over the tumour volume.
Two-dimensional in vivo imaging This was carried out with
a Maestro 500 imaging system (Cambridge Research,
Woburn, MA, USA). For AF 680 measurements, a band
pass filter from 615 nm to 665 nm and a high-pass filter over
700 nm were used for excitation and emission light, respec-
tively. A series of images were acquired at different wave-
lengths and then subjected to spectral unmixing as described
by Gao et al [28] for unmixing the AF 680 fluorescence
pattern from tissue autofluorescence.
Two-dimensional ex vivo imaging This was also carried out
with a Maestro 500 imaging system. Control and RIP-
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hTMEM27-tg mice were injected with 2 mg/kg AF 680–8/9-
mAb or AF 488–8/9-mAb. The animals were killed 72 h
(3 days) after antibody administration, and organs (pancreas,
liver, kidney and spleen) were excised and imaged. For
detection of the AF 488 signal, a band pass filter from
445 nm to 490 nm and a high-pass filter over 515 nm were
used for excitation and emission light, respectively, while
the filter combination described above was used for AF 680
detection. Spectral unmixing was carried out as previously
described [28]. The images were normalised for depth
intensity, exposure time and binning differences.
In vivo PET INS-1E-hTMEM27 (n02) and INS-1E (n02)
tumour-bearing nude mice (19–21 g) were intravenously
injected with 1.5 MBq of the radiotracer, (89Zr-8/9-mAb,
corresponding to 60 μg 8/9-mAb). PET scanning of the
animals was performed at 24 h and 72 h after tracer injection
using small-animal GE VISTA eXplore PET/CT tomograph.
Animals were anaesthetised and scanned for 60 min. After
the PET scan on day 3, the mice were killed, and this was
followed by tissue sampling and gamma counting. Radio-
activity accumulated in tissue samples was expressed as
percentage of the injected dose (%ID)/g tissue. PET data
were reconstructed in a single time frame and analysed
using PMOD software (PMOD Technologies, Zurich, Swit-
zerland). PET data were quantitatively evaluated by ROI
analysis, and the standard uptake value was determined by
normalising the activity concentration in the ROI to the
injected dose per body weight. Imaged data were visualised
by either maximum-intensity projections or horizontal slice
series, which were normalised to the injected dose per body
weight.
Immunohistochemistry Cryo-blocks and sections of insuli-
nomas and pancreas were derived from mice that were
systemically injected with either prelabelled AF 488–8/9-
mAb or AF 488–anti-HA-mAb and were processed as fol-
lows. The excised mouse organs were processed to cryo-
blocks using cryo-preservant medium (optimal cutting tem-
perature [OCT] medium; Tissue-Tek, Sakura, the Nether-
lands) into 10 μm tissue sections. Sections were washed (3×
5 min) with PBS and fixed with 3% paraformaldehyde/2%
sucrose in 1× PBS (30 min) at room temperature (RT),
followed by washing with 1× PBS (3×5 min). Blocking
was performed with 10% normal goat serum/BSA/0.3%
Triton X-100 in 1× PBS (blocking buffer) (30 min at RT).
The sections were incubated with the primary antibody
(either unlabelled 8/9-mAb [F. Hoffmann-La Roche] or
anti-insulin [Linco; No. 4011-01; St Charles, Missouri,
USA]) for 2 h at RT in blocking buffer. Sections were washed
with 1× PBS (3×5 min) and subsequently incubated with AF
488 goat anti-mouse (Invitrogen Life Technologies, Zug,
Switzerland) secondary antibody (dilution 1:400) for 30 min
at RT in blocking buffer. The sections were washed with 1×
PBS (3×5 min) and mounted using ProLong Gold (Molecular
Probes) with DAPI. All sections were visualised using a
fluorescence microscope (Zeiss Axioplan 2), and images were
processed using Zeiss AxioVision (release 4.7) software.
Human adult normal tissue microarrays (T8234708;
BioChain, Newark, CA, USA; 5 μm thick) were stained
with 100 ng/ml Alex Fluor 488–8/9-mAb and insulin
following the procedures described above.
Statistical analysis All quantification was carried out using
GraphPad Prism 5 (http://www.softpedia.com/get/Science-
CAD/GraphPad-Prism.shtml). Error bars represent SD.
p values were calculated using two-way ANOVA; those
smaller than 0.05 were considered significant.
Results
TMEM27 as a potential target for pancreatic beta cell
visualisation A series of mAbs was raised against the beta
cell surface N-glycoprotein, hTMEM27 [19], and clone 8/9
was identified as the hTMEM27-specific mAb (8/9-mAb)
most suitable for imaging applications. This antibody was
labelled with either the dye AF 680 (AF 680–8/9-mAb) or a
chelating ligand containing zirconium-89 (89Zr-8/9-mAb)
for visualisation with fluorescence imaging and PET,
respectively. For histological analysis, 8/9-mAb was
labelled with the dye AF 488 (AF 488–8/9-mAb).
Human tissue samples were used to evaluate the clinical
relevance of hTMEM27 by assessing tissue-specific produc-
tion and binding specificity of 8/9-mAb to TMEM27 in
adult human normal tissue microarrays. US Food and Drug
Administration (FDA) standard adult human tissue micro-
arrays containing samples of pancreas, kidney, liver and
spleen (T8234708) were stained with AF 488–8/9-mAb.
Immunofluorescence analysis of these tissue microarrays
showed TMEM27 expression to be restricted to pancreatic
and kidney samples, with no TMEM27 immunoreactivity in
liver and spleen (Fig. 1a). Importantly, AF 488–8/9-mAb
colocalised with insulin, showing that the staining is beta
cell specific (Fig. 1b).
Expression analysis of hTMEM27 using the 8/9-mAb
antibody in pancreatic sections of C57BL/6 mice (control)
compared with RIP-hTMEM27-tg mice [19] showed dis-
tinct islet staining (Fig. 1c). Co-staining of AF 488–8/9-
mAb and an insulin-specific antibody confirmed the binding
to be beta cell specific in RIP-hTMEM27-tg mice (Fig. 1c).
To determine the level of hTMEM27 in the transgenic
animals compared with humans and thus evaluate its suitabil-
ity as a model for future application in human beta cells, real-
time PCR specific for hTMEM27 was performed on islet
cDNA derived from six different human cadaver donors, four
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RIP-hTMEM27-tg mice and five C57Bl6-negative control
animals, using primer pairs given in ESM Tab. 1. After
normalisation to PDX1 cDNA as a beta cell marker, the ratio
of hTMEM27 in the transgenic mice to that in human material
was about 10:1, while no signal was obtained from the neg-
ative control animals (Fig. 1d). Given that the human islets
used were compromised compared with the murine samples
(see the Methods section), this degree of overexpression was
considered close enough to the hTMEM27 expression that
might be expected in humans in vivo.
In vivo binding specificity and kinetics of 8/9-mAb in mice
bearing subcutaneous insulinomas To characterise binding
properties and distribution kinetics of 8/9-mAb in vivo, we
generated a rat beta cell insulinoma cell line stably expressing
hTMEM27 under the control of a tetracycline transactivator
(INS-1E-hTMEM27). Before in vivo studies, 8/9-mAb bind-
ing was assessed in cell cultures using doxycycline-inducible
INS-1E-hTMEM27 cells. Because of expression leakage in
INS-1E-hTMEM27, the parental INS-1E cells served as con-
trols rather than non-doxycycline-treated cells.
Antibody labelling showed strong uptake of 8/9-mAb
by the INS-1E-hTMEM27 cells compared with controls
(electronic supplementary material [ESM] Fig. 1). The
binding specificity of 8/9-mAb was further confirmed
using the same concentration of anti-HA-mAb on INS-
1E-hTMEM27 cells, where no specific signal was detected
(ESM Fig. 1).
To monitor 8/9-mAb binding in vivo over time, either
INS-1E-hTMEM27 or INS-1E cells were subcutaneously
injected into nude mice. To induce expression of hTMEM27
in the target cell, all tumour-bearing mice were provided
with doxycycline-containing drinking water. After the
tumours had reached a visible size (>3 mm), AF 680–
8/9-mAb was injected i.v. and fluorescence intensity
was measured dynamically during the subsequent 6 days
Fig. 1 TMEM27, a potential target for pancreatic beta cell imaging.
(a) Immunofluorescence images of 5 μm FDA standard adult human
tissue microarrays containing samples of spleen, liver, pancreas and
kidney with AF 488–8/9-mAb, showing uptake in the pancreas and
kidney. Scale bar020 μm. (b) Immunohistochemistry of 10 μm-thick
human pancreatic tissue sections with AF 488–8/9-mAb (identifying
hTMEM27) and insulin staining of the same sections. 8/9-mAb and
insulin colocalisation images show antibody retention in beta cells.
Scale bar050 μm. (c) Immunofluorescence of 10 μm pancreatic sec-
tions from RIP-hTMEM27-tg and normal C57BL6 (control) mice with
8/9-mAb. Insulin staining, for localising beta cells in an islet, is shown
in red and nuclear staining in blue. Scale bar020 μm. (d) Real-time
PCR of cDNA from murine, human and RIP-TMEM27-tg mouse
islets. hTMEM27 levels were determined using primers unique to
hTMEM27. Signals were first normalised to real-time PCR signal
obtained for PDX1 cDNA (as a beta cell normalisation standard) using
primers binding exon flanking sequences identical in human and
mouse PDX1 cDNA sequence, and then to the human TMEM27/
PDX1 ratio. Murine islets, n05, human islets, n06, and RIP-
TMEM27 islets, n04. Error bars represent standard deviations.
***p<0.001. RU 0 relative units
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using FMT [27, 29]. Reconstructed FMT images of the
tumour-bearing nude mice showed strong fluorescence
in the INS-1E-hTMEM27 tumours within 24 h of AF
680–8/9-mAb injection. This signal was retained for the
subsequent 3 days (Fig. 2a), and gradually cleared in
the next 6 days. In contrast, the control (INS1E) mice
injected with AF 680–8/9-mAb displayed significantly
less fluorescence intensity during this 6-day observation
period (Fig. 2a). Similarly no signal was observed in
the INS-1E-hTMEM27 tumour-bearing mice injected
with AF 680–anti-HA-mAb (Fig. 2a).
Quantitative analysis of the fluorescence intensity in all
these tumours revealed that label uptake was highest 24 h
after antibody injection in all cases, and the signal from INS-
1E-hTMEM27 tumours was significantly higher than in the
controls (p00.0001). Thereafter, the fluorescence intensity
decreased in all cases. At 3 days after antibody injection, the
fluorescence intensity in the INS-1E-hTMEM27 tumours
was sevenfold and 17-fold higher than in the controls
(INS-1E and INS-1E-hTMEM27 and anti-HA-mAb, respec-
tively, p00.0001; Fig. 2b).
The in vivo studies were validated microscopically using
cryo-sections derived from tumours collected 3 days after
antibody injection. The INS-1E-hTMEM27 tumours
showed a strong signal with the AF 488–8/9-mAb, but none
with AF 488–anti-HA-mAb (Fig. 2c). The INS-1E tumours
were negative for AF 488–8/9-mAb as well (Fig. 2c). In
terms of antibody specificity, these observations are consis-
tent with in vitro findings in the cell lines (ESM Fig. 1) and
in vivo fluorescence measurements (Fig. 2a, b).
Fig. 2 8/9-mAb targets hTMEM27 in vivo using near-infrared fre-
quency FMT. (a) FMT of a beta cell subcutaneous tumour in a nude
mouse, 3 days after AF 680–8/9-mAb injection. Uptake of AF 680–8/9-
mAb in vivo was observed in INS-1E-hTMEM27 tumours, whereas
INS-1E tumours and AF 680–anti-HA-mAb in INS-1E-hTMEM27
tumours show no specific uptake. Below each animal is the recon-
structed three-dimensional view of the tumours, with the z axis per-
pendicular to the tumour surface. (b) 8/9-mAb pharmacokinetics, in
vivo. Quantification of antibody uptake in tumours (fluorescence in-
tensity measured by FMT), over a 6-day period after injection. There
was a significant difference (p00.0001) in antibody uptake by
hTMEM27-expressing tumours (INS-1E-hTMEM27, AF 680–8/9-
mAb; circles) compared with control tumours (INS-1E, AF 680–8/9-
mAb; triangles) and control antibody (INS-1E-hTMEM27, AF 680–
anti-HA-mAb; squares). a.u., arbitrary units. (c) Histology of tumours
(insulinomas) from the nude mice for antibody localisation. Nuclei were
stained with DAPI (blue); AF 488–8/9-mAb (green). Left column
depicts images at ×20 magnification, and right column is ×60 magni-
fication. Scale bar050 μm
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In vivo PET imaging for antibody specificity in mice
with subcutaneous insulinomas expressing hTMEM27 In
view of potential translational applications of 8/9-mAb-
based beta cell imaging, we performed PET imaging of the
mice bearing either subcutaneous INS-1E-hTMEM27 or
INS-1E tumours. 89Zr was chosen as radionuclide on the
basis of its half-life of 78 h (3 days), which is appropriate for
the pharmacokinetic properties of 8/9-mAb (Fig. 2d). Hence,
8/9-mAb was radiolabelled with 89Zr ([89Zr]-8/9-mAb).
Binding specificity was tested in vivo using INS-1E-
hTMEM27 and INS-1E tumour-bearing mice, which
were administered with 150 MBq [89Zr]-8/9-mAb. The
animals were subjected to PET imaging 24 h and 72 h
after injection. Whole-body images of these animals revealed
significantly higher activity in INS-1E-hTMEM27 tumours
than INS-1E tumours (Fig. 3a and ESM Fig. 2). At 72 h after
injection, the %ID/g in INS-1E-hTMEM27 tumours was six
to seven times higher than in control tumours (p00.001,
Fig. 3b) and comparable to the results obtained using AF-
labelled antibody, indicating specific tracer accumulation due
to expression of the molecular target and a similar perform-
ance of the two imaging methods.
In vivo targeting of beta cells in mouse pancreas using
8/9-mAb To evaluate in vivo binding of 8/9-mAb to its
target, hTMEM27, a biodistribution study was carried out
using AF 680–8/9-mAb. After fluorescent antibody injec-
tions in mice, fluorescence reflectance images were recorded
at multiple wavelengths and spectrally deconvoluted to dis-
criminate the AF 680 signal from non-specific background
fluorescence [28]. Normalised AF 680 signal intensities in an
abdominal ROI in RIP-hTMEM27-tg and control mice
recorded 72 h after antibody administration were compared
(Fig. 4a). The subsequent analysis revealed a 3.3-fold higher
fluorescence intensity in the RIP-hTMEM27-tg mice (Fig. 4b;
p00.01).
To investigate antibody biodistribution in vivo, organs
were harvested from AF 680–8/9-mAb-injected RIP-
hTMEM27-tg and control mice. Subsequently, ex vivo analy-
sis was performed using fluorescence reflectance imaging
including spectral deconvolution (Fig. 4c). The fluorescent
signal in isolated pancreas from RIP-hTMEM27-tg mice
displayed a striking difference in texture from the control
mice. In RIP-hTMEM27-tg mice, the highest fluorescence
uptake was detected in dot-like structures, a pattern that is
reminiscent of the murine islet distribution along pancreatic
ducts (Fig. 4c). This distinct fluorescent signal was absent
from pancreas derived from control mice, displaying only a
diffuse intensity distribution (Fig. 4c). The normalised pan-
creatic fluorescence signal was 0.021±0.014 in RIP-
hTMEM27-tg mice compared with 0.009±0.0006 in control
animals, although this difference did not reach statistical sig-
nificance (p00.08) because of higher degree of variation in
the hTMEM27-associated signal. No significant difference in
fluorescence intensity was found in the other organs (Fig. 4d).
To further assess the enriched pancreatic signal, magni-
fied images of pancreas derived from RIP-hTMEM27-tg
mice showed antibody-associated fluorescence localised to
islet-like structures (Fig. 4e), marked as fluorescent hot
spots. In contrast, the control mouse pancreas showed minor
background signal in the equivalent regions, with the only
perceivable signal arising from non-pancreatic connective
tissue at the periphery (Fig. 4e). Quantitative analysis of
these images revealed that the fluorescent intensity in the
hotspots observed in transgenic mice was sevenfold higher
than the diffuse signal in the corresponding regions of con-
trol mice (Fig. 4f; p00.0001).
To elucidate the origin of the fluorescent hot spots, we
microscopically analysed pancreatic sections from organs taken
72 h after AF 488–8/9-mAb injection. Co-staining of these
sections with an insulin-specific antibody identified the hot spots
as islets comprising pancreatic beta cells in theRIP-hTMEM27-tg
Fig. 3 [89Zr]–8/9-mAb targets hTMEM27 in vivo. (a) PET of beta cell
tumour-bearing nude mice, 3 days after [89Zr]–8/9-mAb injection.
(b) Radioactive uptake shown as %ID/g (p00.001). Maximum uptake
was seen in tumour (a, middle arrow) compared with liver (a, top
arrow) or site of tail injection (a, bottom arrow). Tumour uptake was
much higher in INS-1E-hTMEM tumour bearing mice
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mice (Fig. 4g), whereas no AF 488–8/9-mAb staining
was observed in islet regions of the control mice (Fig. 4g).
Discussion
State-of-the-art beta cell imaging strategies [30, 31] have to
be able to monitor beta cells in a longitudinal manner. This
requires identification of molecular entities that are highly
specific for beta cells, which can be targeted using molec-
ular imaging probes. Ideally, these targets should not only
reflect the beta cell functional status, but should also be
preserved throughout a wide patient population. A promis-
ing candidate that meets these specifications is the cell sur-
face N-glycoprotein, TMEM27, which is exclusively
expressed on pancreatic beta cells and kidney [19]. In
addition, TMEM27 has a functional relevance in beta cell
proliferation and insulin secretion [19, 32], and, although its
levels were found to be decreased in islets derived from
diabetic donors compared with healthy controls, it was still
present in these patients [33, 34].
In our approach of targeting TMEM27, we characterised
a mAb against hTMEM27, 8/9-mAb, which specifically
labels human pancreatic beta cells and parts of human
kidney, as an imaging tool. We used fluorescent labelling
of antibodies in combination with FMT as an experimental
approach, and radiolabelling in combination with PET
for potential translational applications (Fig. 2), using
hTMEM27-expressing insulinoma xenograft nude mice
and RIP-hTMEM27-tg mice as well as models for the
human beta cell. The former revealed a high signal-to-
background contrast in subcutaneous tumours 1 day after
Fig. 4 8/9-mAb hTMEM27 antibody specifically targets mouse pan-
creatic beta cells in vivo. (a) RIP-hTMEM-tg and control mice (n03),
3 days after AF 680–8/9-mAb injection and spectral deconvolution
showing different fluorescence retention. (b) Quantification of the
normalised fluorescent intensities from these mice (†p00.01). (c) Ex
vivo near-infrared imaging of mouse (n03) organs (L, liver; K, kidney;
S, spleen; P, pancreas) from (a), 3 days after i.v. injection of AF 680–8/9-
mAb. (d) Fluorescence intensity in organs from transgenic (black
bar) and control (white bar) mice; p value for pancreas is 0.084. (e) Ex
vivo imaging of mouse organs harvested 3 days after injection of AF
488–8/9-mAb. The images were unmixed (spectral deconvolution) to
separate antibody signal (in green) from tissue background (red). Islet
uptake of the fluorescently labelled antibody can be seen in pancreas
from RIP-h-TMEM27 mice as green hot spots (arrowheads). (f) Quan-
tification of the mean fluorescent signal intensity/exposure time of pan-
creases from RIP-hTMEM27-tg and control mice (‡p00.0001). (g)
Histological analysis of the pancreas from RIP-hTMEM27-tg and
C57BL6 (control) mice after i.v. tail vein injection of AF 488–8/9-
mAb, showing antibody uptake in the islet beta cells in RIP-
hTMEM27-tg mouse pancreas, while control mouse pancreatic sections
stained negative. The sections were further stained for insulin (red). The
AF 488–8/9-mAb staining colocalised with insulin staining for pancreatic
beta cells. Scale bar020 μm
2414 Diabetologia (2012) 55:2407–2416
injection of AF 680–8/9-mAb (Fig. 2a–c), and similarly we
observed high label retention in the pancreatic islets of the
RIP-hTMEM27-tg mice (Fig. 1d), comparable to the findings
derived from human pancreatic sections (Fig. 1a). This study
thus represents a novel beta cell assessment method, namely an
antigen–antibody pair-mediated (humanised) beta cell imaging
approach. The observation that transcript levels of hTMEM27
in islets from human cadaver donors were ten times lower than
in RIP-hTMEM27-tg mice may indicate that the sensitivity of
the antibody-mediated approach will have to be improved for
clinical applications. One possible way to further increase the
antibody-mediated hTMEM27 signal is to administer a beta-
secretase (BACE) inhibitor before and during the antibody
treatment, thereby preventing TMEM27 degradation by
BACE2 and significantly increasing antigen availability, since
BACE2 inhibition has been shown to increase TMEM27
signals at least 3–4-fold in isolated human islets [33].
The signal generated at the target site is essentially gov-
erned by the number of binding sites expressed by the target
and by the binding affinity and bioavailability of the probe.
Unspecific signals are largely determined by the rate of
probe elimination from the circulation, which also dictates
its retention in the extracellular space. Fluorescence micro-
scopy revealed that the beta cell-specific fluorescence signal
originated from probe molecules in the beta cells, indicating
internalisation of 8/9-mAb (Figs 1, 2 and 4). Internalisation
contributed to longer retention of labelled probe in the beta
cells (both in tumours and pancreatic islets) and potentially
also led to accumulation due to probe trapping associated
with amplification of the fluorescence signal. TMEM27 is
an ideal target for such an accumulation, as, at any given
point in time, only 10% of the TMEM27 population is found
at the cell surface [35], similar to other signalling receptors,
indicating vibrant trafficking and internalisation. Our study
may also suggest that dynamically trafficking cell surface
proteins are potentially powerful targets for antibody-based
imaging approaches. In spite of high specific binding of the
8/9-mAb-based probe, the low fraction of beta cells in
pancreatic tissue requires specific local enrichment of an
imaging probe by a factor of at least 100 compared with
the exocrine tissue, blood and adjacent organs, in order to
enable reliable assessment of changes in beta cells in vivo.
This value may be reached with further technological devel-
opment such as: (1) optimising the probe’s pharmacokinetic
properties; (2) using antibody fragments or antibodies with
even higher affinity for hTMEM27; (3) using antibodies that
will only bind to the extracellular part of TMEM27, which
stays membrane associated even after cleavage (human
amino acid residues 126–141) and therefore may lead to
lower background levels, as binding to shed circulating
TMEM27 will be avoided; (4) using a BACE inhibitor,
which prevents hTMEM27 degradation, thereby increasing
antigen availability.
Nevertheless, fluorescence imaging constitutes an
attractive imaging modality for research purposes, as it
uses stable labels suitable for monitoring animals over
extended periods of time and allows direct validation
through fluorescence histology, and translation to clinics
can be readily achieved by replacing the fluorescent
label with a radionuclide label.
In summary, we have demonstrated that selective target-
ing and imaging of beta cells using an antibody-mediated
approach is feasible in vivo, which is relevant with regard to
both preclinical and clinical applications, despite current
technological limitations. The fact that high antibody reten-
tion has been found in the beta cells of human pancreatic
sections and humanised beta cells in vivo makes 8/9-mAb a
potential candidate for clinical application, and hTMEM27
an attractive antigen as an imaging target.
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